Rivaroxaban for Afib

In this large trial of >14,000 patients with non-valvular afib, they were randomized to rivaroxaban (oral Xa inhibitor) or warfarin. The primary endpoint (stroke or systemic embolism) occurred in significantly fewer in the rivaroxaban vs warfarin groups (1.7% vs 2.2% per year). Although not yet FDA approved, rivaroxaban will soon be added to the oral arsenal of anti-coagulants for Afib stroke prevention (abstract)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment